Survodutide meets cardiovascular safety threshold in Phase 3 trial, but heart-protective benefits remain unproven
The dual receptor agonist met its cardiovascular noninferiority endpoint, adding important evidence to its obesity development program; whether it can reduce cardiovascular events and whether patients can tolerate long-term treatment remain separate tests.